Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16302023 | 0.93 | POLB (0.45) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL5594524 | 0.89 | POLB (0.65) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL21428430 | 0.87 | POLB (0.58) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL20943327 | 0.85 | POLB (0.57) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL22018193 | 0.85 | POLB (0.57) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL9153460 | 0.85 | ALDH1A1 (0.62) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL847825 | 0.85 | ALDH1A1 (0.62) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL14590616 | 0.84 | POLB (0.50) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL12311389 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBLMNAALDH1A1HTT | |
| SCHEMBL11480332 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBLMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114127044-A | Ionizable amine lipids and lipid nanoparticles | 英特利亚治疗股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3518334-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION ADDITIVE, NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAID ADDITIVE | LG CHEMICAL LTD (KR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3778571-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | Bioway, Inc. (KR) | 2021-02-17 | — | — | EP | disclosed |
| US-20200157048-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | BIOWAY., INC (KR) | 2020-05-21 | — | — | US | disclosed |
| WO-2019190177-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | 주식회사 바이오웨이 | 2019-10-03 | — | — | WO | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157048-A1 | (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE | PCK1, PCK2, ACACB | SMN1; SMN2 4751/4885POLB 2434/4885LMNA 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.